NASDAQ:APTX - Aptinyx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.45 -0.03 (-0.86 %) (As of 05/22/2019 04:00 PM ET)Previous Close$3.48Today's Range$3.36 - $3.535252-Week Range$3.27 - $32.25Volume123,812 shsAverage Volume406,428 shsMarket Capitalization$115.79 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois. Receive APTX News and Ratings via Email Sign-up to receive the latest news and ratings for APTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APTX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.aptinyx.com/ Phone847-871-0377Debt Debt-to-Equity RatioN/A Current Ratio23.43 Quick Ratio26.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.57 million Price / Sales17.62 Cash FlowN/A Price / Cash FlowN/A Book Value$4.01 per share Price / Book0.86Profitability EPS (Most Recent Fiscal Year)($2.64) Net Income$-53,280,000.00 Net Margins-1,166.40% Return on Equity-37.53% Return on Assets-35.89%Miscellaneous EmployeesN/A Outstanding Shares33,562,000Market Cap$115.79 million Next Earnings Date8/13/2019 (Estimated) OptionableNot Optionable Aptinyx (NASDAQ:APTX) Frequently Asked Questions What is Aptinyx's stock symbol? Aptinyx trades on the NASDAQ under the ticker symbol "APTX." How were Aptinyx's earnings last quarter? Aptinyx Inc (NASDAQ:APTX) released its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.04. The firm earned $0.89 million during the quarter, compared to analysts' expectations of $1 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%. View Aptinyx's Earnings History. When is Aptinyx's next earnings date? Aptinyx is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Aptinyx. What price target have analysts set for APTX? 5 brokers have issued twelve-month target prices for Aptinyx's shares. Their forecasts range from $8.00 to $22.00. On average, they anticipate Aptinyx's stock price to reach $15.00 in the next year. This suggests a possible upside of 334.8% from the stock's current price. View Analyst Price Targets for Aptinyx. What is the consensus analysts' recommendation for Aptinyx? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx. What are Wall Street analysts saying about Aptinyx stock? Here are some recent quotes from research analysts about Aptinyx stock: 1. According to Zacks Investment Research, "Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. " (5/20/2019) 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month PT of $12 on APTX. With an initial focus on large indications within chronic pain, there are multiple nervous system disorder opptys for the company’s candidates that have a better safety/tolerability profile relative to historical NMDAr-based treatments like ketamine. Data from pre-clinical models look promising, and important PoC trial data should emerge this year. Valuation Summary We use a discounted NPV revenue calculation that yields ~$10 for NYX-2925 in DPN and ~$2 for pipeline placeholder ($75M total NPV) in fibromyalgia." (4/30/2019) Has Aptinyx been receiving favorable news coverage? Media headlines about APTX stock have trended negative recently, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptinyx earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Aptinyx's key competitors? Some companies that are related to Aptinyx include Corbus Pharmaceuticals (CRBP), NuCana (NCNA), BioSpecifics Technologies (BSTC), Corium International (CORI), ProQR Therapeutics (PRQR), INDIVIOR PLC/S (INVVY), Albireo Pharma (ALBO), DiaMedica Therapeutics (DMCAF), Dynavax Technologies (DVAX), Arcus Biosciences (RCUS), Savara (SVRA), Cyclerion Therapeutics (CYCN), Kalvista Pharmaceuticals (KALV), Achillion Pharmaceuticals (ACHN) and Collegium Pharmaceutical (COLL). What other stocks do shareholders of Aptinyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include WABCO (WBC), Ocular Therapeutix (OCUL), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Fibrocell Science (FCSC), Inpixon (INPX), Spark Therapeutics (ONCE), OncoSec Medical (ONCS), Progenics Pharmaceuticals (PGNX) and Rigel Pharmaceuticals (RIGL). Who are Aptinyx's key executives? Aptinyx's management team includes the folowing people: Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)Ms. Betty Y. Jang, VP of Legal Affairs (Age 50) When did Aptinyx IPO? (APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are Aptinyx's major shareholders? Aptinyx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include New Leaf Venture Partners L.L.C. (10.53%), BlackRock Inc. (3.29%), Morgan Stanley (1.53%), Marshall Wace LLP (0.75%), JPMorgan Chase & Co. (0.66%) and Spark Investment Management LLC (0.18%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Robert J Hombach and Torsten M Madsen. View Institutional Ownership Trends for Aptinyx. Which major investors are selling Aptinyx stock? APTX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and State of Wisconsin Investment Board. View Insider Buying and Selling for Aptinyx. Which major investors are buying Aptinyx stock? APTX stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Marshall Wace LLP, New Leaf Venture Partners L.L.C., Spark Investment Management LLC, JPMorgan Chase & Co., Alambic Investment Management L.P., Dimensional Fund Advisors LP and Swiss National Bank. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Robert J Hombach and Torsten M Madsen. View Insider Buying and Selling for Aptinyx. How do I buy shares of Aptinyx? Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aptinyx's stock price today? One share of APTX stock can currently be purchased for approximately $3.45. How big of a company is Aptinyx? Aptinyx has a market capitalization of $115.79 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. What is Aptinyx's official website? The official website for Aptinyx is http://www.aptinyx.com/. How can I contact Aptinyx? Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected] MarketBeat Community Rating for Aptinyx (NASDAQ APTX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 51 (Vote Outperform)Underperform Votes: 53 (Vote Underperform)Total Votes: 104MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: How Do Front-End Loads Impact an Investment? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.